<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349996</url>
  </required_header>
  <id_info>
    <org_study_id>ID3-20170704</org_study_id>
    <nct_id>NCT03349996</nct_id>
  </id_info>
  <brief_title>Belgian Trial Investigating the LifeStream Stent in Complex TASC C and D Iliac Lesions</brief_title>
  <acronym>BELSTREAM</acronym>
  <official_title>Belgian Physician-initiated Trial Investigating the LifeStream Peripheral Stent Graft System for the Treatment of Complex TASC C and D Iliac Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ID3 Medical</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ID3 Medical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BELSTREAM Trial investigates the efficacy of the LifeStream Peripheral Stent Graft System&#xD;
      in the treatment of iliac stenotic or occlusive lesions (TASC C and D). An expected total of&#xD;
      70 patients will be treated. The lesion is located within the native Iliac arteries. Prior to&#xD;
      stenting with the LifeStream Peripheral Stent Graft System, pre-dilatation can be performed&#xD;
      according to the physician's discretion. Also post-dilatation can be performed according to&#xD;
      the physician's discretion. Patients will be invited for a follow-up visit at 1, 6 and 12&#xD;
      month post-procedure. The primary efficacy endpoint of the study is the primary patency at 12&#xD;
      months. The primary safety endpoint is the freedom of periprocedural Serious Adverse Events&#xD;
      (SAEs). Secondary endpoint include primary patency rate at 1 and 6 month, stent graft&#xD;
      occlusion rate at pre-discharge, 1, 6 and 12 month follow-up, anke-brachial index (ABI) at 1,&#xD;
      6 and 12-month follow-up, amputation rate at 1, 6 and 12-month follow-up, technical success&#xD;
      and clinical success at 1, 6 and 12-month follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this clinical investigation is to evaluate, in a controlled setting, the&#xD;
      long-term safety and efficacy of the LifeStream Peripheral Stent Graft System in clinical&#xD;
      settings post CE-certification when used according to the indications of the IFU with focus&#xD;
      on the treatment of complex TASC C and D iliac lesions.&#xD;
&#xD;
      Patients will be selected based on the investigator's assessment, evaluation of the&#xD;
      underlying disease and the eligibility criteria. The patient's medical condition should be&#xD;
      stable, with no underlying medical condition which would prevent them from performing the&#xD;
      required testing or from completing the study. Patients should also be geographically stable,&#xD;
      willing and able to cooperate in this clinical study and remain available for long-term&#xD;
      follow-up. A patient is considered enrolled in the study after obtaining the patients&#xD;
      informed consent, if there is full compliance with the study eligibility criteria and after&#xD;
      successful guidewire passage through the study target lesion.&#xD;
&#xD;
      Prior to the index procedure the following tests and clinical data will be collected:&#xD;
      informed consent for data collection, demographics, medical history, medication record,&#xD;
      physical examination, clinical category of chronic limb ischemia (Rutherford category) and&#xD;
      resting ankle-brachial index (ABI).&#xD;
&#xD;
      During the procedure, the vascular access can be achieved to the investigator's standard&#xD;
      clinical practice. After successful lesion passage, diagnostic angiography of the lesion area&#xD;
      and distal run-off is performed and angiographic measurements (vessel diameter, percentage&#xD;
      stenosis and lesion length) are collected. At the physician's discretion, the patient&#xD;
      receives at least 1 LifeStream Peripheral Stent Graft System. Pre- and post-dilatation are&#xD;
      according to the physician's discretion. No other adjunctive therapies (atherectomy, laser)&#xD;
      are allowed. The complete iliac vasculature should be treated in one single session, staged&#xD;
      interventions are not allowed. All outflow-limiting lesions must be treated according to the&#xD;
      hospital treatment standard.&#xD;
&#xD;
      The regular follow-ups are necessary to monitor the condition of the patient and the&#xD;
      stent/procedure. Patients will be invited for a follow-up visit at 1, 6 and 12 months after&#xD;
      the index procedure. The following data will be collected during these follow-up visit:&#xD;
      medication record, physical examination, rutherford categorization, ABI and color flow&#xD;
      doppler ultrasound.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Target lesion without a hemodynamically significant stenosis on duplex ultrasound (&gt;50%, systolic velocity ratio greater than 2.5) and with freedom from Target Lesion Revascularization (TLR) within 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from periprocedural Serious Adverse events (SAEs)</measure>
    <time_frame>During index procedure</time_frame>
    <description>Periprocedural SAEs as defined according to the International Organization for Standardization guidelines (ISO) 14155:2011</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary patency at 1 and 6 months post procedure</measure>
    <time_frame>1 and 6 months post-procedure</time_frame>
    <description>Target lesion without a hemodynamically significant stenosis on duplex ultrasound (&gt;50%, systolic velocity ratio greater than 2.5) and with freedom from Target Lesion Revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent graft occlusion rate</measure>
    <time_frame>Pre-discharge, 1, 6 and 12 month follow-up</time_frame>
    <description>Occlusion of the stent graft system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial index (ABI)</measure>
    <time_frame>1, 6 and 12 month post-procedure</time_frame>
    <description>ABI at follow-up compared with the baseline ABI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation rate</measure>
    <time_frame>1, 6 and 12 months post-procedure</time_frame>
    <description>Any amputation above the knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>Index procedure</time_frame>
    <description>Ability to achieve final residual angiographic stenosis no greater than 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>1, 6 and 12 months post-procedure</time_frame>
    <description>Improvement of Rutherford classification compared to the pre-procedure classification</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>LifeStream Peripheral Stent Graft System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with the LifeStream Peripheral Stent Graft System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LifeStream Peripheral Stent Graft System</intervention_name>
    <description>Patients will be treated with the LifeStream Peripheral Stent Graft System</description>
    <arm_group_label>LifeStream Peripheral Stent Graft System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General inclusion criteria:&#xD;
&#xD;
          -  Corresponding to the CE-mark indications/contra-indications and according to the&#xD;
             current medical guidelines for minimally invasive peripheral interventions.&#xD;
&#xD;
          -  Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable&#xD;
             for stenting (on indication for primary stenting, based on the discretion of the&#xD;
             investigator)&#xD;
&#xD;
          -  Patient presenting a score from 2 to 4 following Rutherford classification&#xD;
&#xD;
          -  Patient is willing to comply with specified follow-up evaluations at the specified&#xD;
             times for the duration of the study&#xD;
&#xD;
          -  Patient is &gt;18 years old&#xD;
&#xD;
          -  Patient (or their legal representative) understands the nature of the procedure and&#xD;
             provides written informed consent, prior to enrolment in the study&#xD;
&#xD;
          -  Patient is eligible for treatment with the Lifestream Peripheral Stent Graft System&#xD;
             (Bard)&#xD;
&#xD;
        Angiographic inclusion criteria&#xD;
&#xD;
          -  The target lesion is either a modified TASC-II class C or D lesion with one of the&#xD;
             listed specifications:&#xD;
&#xD;
               -  Type C lesions&#xD;
&#xD;
                    -  Bilateral Common Iliac Artery occlusions&#xD;
&#xD;
                    -  Bilateral External Iliac Artery stenoses 3-10 cm long not extending into the&#xD;
                       Common Femoral Artery&#xD;
&#xD;
               -  Type D lesions&#xD;
&#xD;
                    -  Unilateral occlusions of both Common Iliac and External Iliac Artery&#xD;
&#xD;
                    -  Diffuse disease involving the aorta bifurcation&#xD;
&#xD;
                    -  Bilateral occlusions of External Iliac Artery&#xD;
&#xD;
          -  The target lesion has angiographic evidence of stenosis or restenosis post&#xD;
             percutaneous transluminal angioplasty (PTA) &gt; 50% or occlusion which can be passed&#xD;
             with standard guidewire manipulation&#xD;
&#xD;
          -  There is angiographic evidence of a patent Common and Deep Femoral Artery&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  PTA is technically not possible (not feasible to access the lesion or a defect with&#xD;
             the guidewire or balloon catheter)&#xD;
&#xD;
          -  Presence of an aneurysm immediately adjacent to the site of stent graft implantation&#xD;
&#xD;
          -  Lesions in or adjacent to essential collaterals(s)&#xD;
&#xD;
          -  Lesions in locations subject to external compression&#xD;
&#xD;
          -  Heavily calcified lesions resistant to PTA&#xD;
&#xD;
          -  Patients with diffuse distal disease resulting in poor stent graft outflow&#xD;
&#xD;
          -  Patients with a history of coagulation disorders&#xD;
&#xD;
          -  Patients with aspirin allergy or bleeding complications and patients unable or&#xD;
             unwilling to tolerate anticoagulant/antiplatelet therapy and/or non-responders to&#xD;
             anticoagulant/antiplatelet therapy&#xD;
&#xD;
          -  Fresh thrombus formation&#xD;
&#xD;
          -  Patients with known hypersensitivity to the stent material (L605) and or&#xD;
             polytetrafluroethylene (PTFE)&#xD;
&#xD;
          -  The target lesion is either a modified TASC-II class C or D lesion with aortic or&#xD;
             common femoral lesion involvement:&#xD;
&#xD;
               -  Type C lesions&#xD;
&#xD;
                    -  Unilateral External Iliac Artery stenosis extending into the Common Femoral&#xD;
                       Artery&#xD;
&#xD;
                    -  Unilateral External Iliac Artery occlusion that involves the origins of the&#xD;
                       Internal Iliac and/or Common Femoral Artery&#xD;
&#xD;
                    -  Heavily calcified unilateral External Iliac Artery occlusion with&#xD;
                       involvement of the Common Femoral Artery&#xD;
&#xD;
               -  Type D lesions&#xD;
&#xD;
                    -  Infra-renal aortoiliac occlusion&#xD;
&#xD;
                    -  Iliac stenoses in patients with an Abdominal Aortic Aneurysm (AAA) requiring&#xD;
                       treatment and not amenable to endograft placement or other lesions requiring&#xD;
                       open aortic or iliac surgery&#xD;
&#xD;
                    -  Diffuse multiple stenoses involving the unilateral Common Iliac, External&#xD;
                       Iliac and Common Femoral Artery&#xD;
&#xD;
          -  Previously implanted stent(s) at the same lesion site&#xD;
&#xD;
          -  Reference segment diameter is not suitable for the available stent graft design&#xD;
&#xD;
          -  Untreatable lesion located at the distal outflow arteries&#xD;
&#xD;
          -  Use of alternative therapy (e.g. atherectomy, cutting balloon, drug coated balloon&#xD;
             (DCB), laser, radiation therapy) as part of the index procedure&#xD;
&#xD;
          -  Patients refusing treatment&#xD;
&#xD;
          -  Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are&#xD;
             contraindicated&#xD;
&#xD;
          -  Perforation at the angioplasty site evidenced by extravasation of contrast medium&#xD;
&#xD;
          -  Patients with a history of prior life-threatening contrast medium reaction&#xD;
&#xD;
          -  Patients with uncorrected bleeding disorders&#xD;
&#xD;
          -  Female patient with child bearing potential not taking adequate contraceptives or&#xD;
             currently breastfeeding&#xD;
&#xD;
          -  Life expectancy of less than twelve months&#xD;
&#xD;
          -  Any planned surgical intervention/procedure within 30 days of the study procedure&#xD;
&#xD;
          -  Any patient considered to be hemodynamically unstable at onset of procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koen Deloose, MD</last_name>
    <role>Study Director</role>
    <affiliation>ID3 Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>O.L.V. Hospital</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Z.N.A.</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.Z. Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Z.O.L.</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R.Z. Heilig Hart</name>
      <address>
        <city>Tienen</city>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

